Cover Image
市場調查報告書

NPS+:氣喘/慢性阻塞性肺病 (美國)

NPS+ Asthma/COPD (US)

出版商 FirstWord 商品編碼 358505
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
NPS+:氣喘/慢性阻塞性肺病 (美國) NPS+ Asthma/COPD (US)
出版日期: 2016年05月01日 內容資訊: 英文
簡介

本報告依據100名美國的呼吸系統科醫生、一般醫生的調查結果,提供醫生對9個氣喘/慢性阻塞性肺病的領導品牌產品的使用趨勢和各種見解比較、分析,支援測量客戶忠誠度的NPS (淨推薦值) 指標的改善。

主要氣喘/慢性阻塞性肺病 治療藥

  • Advair (fluticasone propionate/salmeterol; GSK)
  • Arcapta (indacaterol; Novartis)
  • Breo Ellipta (fluticasone furoate/vilanterol; GSK)
  • Daliresp (roflumilast; AstraZeneca)
  • Nucala (mepolizumab; GSK)
  • Spiriva (tiotropium; Boehringer)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Tudorza (aclidinium; AstraZeneca)
  • Xolair (omalizumab; Novartis/Roche)

調查內容範例:影響品牌忠誠的主要課題

  • 氣喘/慢性阻塞性肺病市場的滿意度
  • 醫生對各品牌藥的忠誠度等級
  • 各品牌推薦者推薦的其他品牌數
  • 各品牌推薦者、批判者推薦的其他品牌
  • 在推薦者及批判者間的各品牌的市場佔有率
  • 如果批判者成為推薦者可得到的市場佔有率
  • 推薦者、中立者、批判者與各品牌相關的訊息
  • 品牌DNA:各品牌藥相關的醫生本身的話
目錄
Product Code: 596200657

FDCs are a hit in the US Asthma/COPD market. How does your brand measure up?

In a recent brand satisfaction survey of US pulmonologists and GPs, 3 of the 4 leading asthma/COPD brands were fixed-dose combinations. Did one of them take top spot? Find out how they scored, how single agent therapies stack up, and where your brand ranks.

This report compares brand loyalty for 9 major Asthma/COPD treatments from AstraZeneca, Boehringer, GSK, Novartis, and Roche.

Based on the respected net promoter score (NPS), it shows you:

  • How likely doctors are to recommend your brand-and your competitors.
  • Which marketing messages are likely to succeed.
  • Your “Brand DNA”: What doctors really think about your brand.

Easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear-information you can use to improve your brand's health, and boost your market share.

Get Answers to Key Questions about Asthma/COPD Treatments

  • Advair (fluticasone propionate/salmeterol; GSK): Advair and Symbicort have similar NPS scores. Which brand has more Promoters?
  • Arcapta (indacaterol; Novartis): Is lack of experience with Arcapta preventing doctors from recommending it?
  • Breo Ellipta (fluticasone furoate/vilanterol; GSK): How concerned are doctors about Breo Ellipta's cost and insurance restrictions?
  • Daliresp (roflumilast; AstraZeneca): Does Daliresp earn more doctor recommendations for being effective or easy to administer?
  • Nucala (mepolizumab; GSK): Nucala is recommended by Promoters of every other brand but which?
  • Spiriva (tiotropium; Boehringer): Are Spiriva's Passives closer to becoming Promoters or Detractors?
  • Symbicort (budesonide/formoterol; AstraZeneca): How do some Symbicort Promoters and Detractors say it compares to Advair?
  • Tudorza (aclidinium; AstraZeneca): Could patients' difficulties with its unique inhaler be preventing Detractors from recommending Tudorza?
  • Xolair (omalizumab; Novartis/Roche): Which brand stands to gain more share by converting Detractors into Promoters, Breo Ellipta, Tudorza, or Xolair?

Top Takeaways

  • Four of the nine surveyed brands have a positive NPS: But the top three score 2-3 times as high as the nearest competitor.
  • FDCs doing well: Fixed-dose combination therapies tend to outscore monotherapies overall, earning 3 of the top 4 Net Promoter Scores.
  • Three brands poised for a massive share gain: if they can win over their Detractors and turn them into Promoters. One of the three is a top-4 brand.
  • Doctors not afraid to try new treatments: 90-100% of nearly every brand's Promoters also recommend one newer-to-market brand.
  • Moderate satisfaction, low exclusivity: over 25% of doctors surveyed are unsatisfied with available asthma/COPD drugs. Less than 15% promote one brand exclusively.
  • Cost a concern for two brands: For one monotherapy and one FDC, cost effectiveness is a top-3 driver of doctor recommendations.
  • Doctors switch brands freely: Loyalty scores are low for all brands. Brand Promoters recommend more than 5 other brands on average.
  • Leading brands are the same in US, EU5: Although the rankings are slightly different, the same four brands earn the highest satisfaction scores in both regions.

A Report Based on Expert Knowledge

We surveyed 100 US pulmonologists and general practitioners chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between April 7th and April 14th, 2016.

Explore Important Brand Loyalty Issues

NPS+ asthma/COPD (US) explores key issues affecting brand loyalty for drug manufacturers. You'll learn:

  • How satisfied the asthma/COPD market is.
  • How loyal doctors are to your brand.
  • How many other brands your Promoters recommend.
  • Which other brands your Promoters and Detractors recommend.
  • How much market share your brand has among Promoters and Detractors.
  • How much market share you stand to gain by converting Detractors into Promoters.
  • Which messages Promoters, Passives and Detractors associate with your brand.
  • Your brand DNA: what doctors really think of your brand-in their own words.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:

  • Detractors are those who answer 0 - 6.
  • Passives are those who answer 7 - 8.
  • Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors' own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Back to Top